Free Trial

Nanobiotix (NBTX) Competitors

Nanobiotix logo
$5.12 +0.34 (+6.99%)
As of 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NBTX vs. LENZ, CRMD, OCS, RCUS, AVXL, COGT, CMRX, CDMO, AVBP, and SNDX

Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.

Nanobiotix vs. Its Competitors

LENZ Therapeutics (NASDAQ:LENZ) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 6.9% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LENZ TherapeuticsN/A -23.74% -22.65%
Nanobiotix N/A N/A N/A

LENZ Therapeutics has higher earnings, but lower revenue than Nanobiotix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENZ TherapeuticsN/AN/A-$49.77M-$1.77-18.07
Nanobiotix$39.18M6.16-$73.73MN/AN/A

In the previous week, LENZ Therapeutics had 1 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Nanobiotix. LENZ Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENZ Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nanobiotix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

LENZ Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

LENZ Therapeutics presently has a consensus price target of $46.60, suggesting a potential upside of 45.72%. Nanobiotix has a consensus price target of $8.00, suggesting a potential upside of 56.10%. Given Nanobiotix's higher probable upside, analysts clearly believe Nanobiotix is more favorable than LENZ Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENZ Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Nanobiotix
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

LENZ Therapeutics beats Nanobiotix on 9 of the 13 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBTX vs. The Competition

MetricNanobiotixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$241.54M$2.38B$5.48B$8.94B
Dividend YieldN/A1.78%5.24%4.05%
P/E RatioN/A8.9027.3120.15
Price / Sales6.16493.23372.7693.81
Price / CashN/A21.7726.2128.59
Price / Book-3.394.537.975.61
Net Income-$73.73M$31.26M$3.17B$248.49M
7 Day Performance6.22%2.87%2.72%6.17%
1 Month Performance8.81%3.83%2.15%7.89%
1 Year Performance-3.30%0.65%33.95%21.19%

Nanobiotix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBTX
Nanobiotix
1.6895 of 5 stars
$5.13
+7.0%
$8.00
+56.1%
-13.1%$241.54M$39.18M0.00100News Coverage
Positive News
Gap Up
LENZ
LENZ Therapeutics
1.3351 of 5 stars
$29.31
-2.9%
$46.60
+59.0%
+74.4%$849.45MN/A-16.56110
CRMD
CorMedix
2.7461 of 5 stars
$12.32
-1.4%
$17.14
+39.1%
+177.2%$847.81M$43.47M56.0030High Trading Volume
OCS
Oculis
1.7349 of 5 stars
$19.41
+0.3%
$35.33
+82.0%
+60.7%$844.87M$780K-7.352
RCUS
Arcus Biosciences
2.784 of 5 stars
$8.17
+2.8%
$21.29
+160.5%
-41.7%$841.79M$258M-1.95500
AVXL
Anavex Life Sciences
3.5802 of 5 stars
$9.22
-2.7%
$44.00
+377.2%
+138.4%$809.33MN/A-16.7640
COGT
Cogent Biosciences
2.6022 of 5 stars
$7.18
+1.1%
$14.43
+101.0%
+10.8%$808.38MN/A-3.9080Trending News
Analyst Forecast
Options Volume
Gap Up
CMRX
Chimerix
0.627 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6898 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
AVBP
ArriVent BioPharma
1.7487 of 5 stars
$21.77
-5.0%
$40.00
+83.7%
+8.4%$783.81MN/A-5.7740
SNDX
Syndax Pharmaceuticals
3.1324 of 5 stars
$9.36
+3.5%
$35.80
+282.5%
-58.3%$777.87M$23.68M-2.42110

Related Companies and Tools


This page (NASDAQ:NBTX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners